Image
DEEP DIVE ANALYSIS • NSE: NEWGEN • FY26 RESULTS Newgen Software Technologies Ltd: From ₹1,336 TO ₹493 — Valuation Reset or the Next Enterprise AI Compounder?  What the Q4 FY26 Numbers Actually Reveal Beneath the Midcap IT Bloodbath By SUMAN MUKHOPADHYAY | SumanSpeaks Independent Research • June 02, 2026 Newgen Software Technologies Ltd (Rs. 493)   was last trading at a pproximately ₹493 — down nearly 63% from its 52-week high near ₹1,336. In most cases, such a collapse signals severe business deterioration. But Newgen’s FY26 financials tell a far more complicated story. The company remains debt-light, highly profitable, cash-generative, and structurally positioned in one of the most important enterprise themes globally: AI-enabled workflow orchestration. Yet the stock has suffered one of the sharpest valuation compressions in the Indian en...
Tit - bits
#The BSE Sensex is now seen at 41,425.75 or
Photo: Seeking Alpha 
down just 99.75  points (-0.25%) while NSE's Nifty is trading at 12,196.55 or down only 25.40 points (-0.23%). This is much improvement from the level when the Sensex nosedived 200 - points. 
Market sentiment was affected by the fact that  International Monetary Fund (IMF) loweried India's growth forecast, apart from subdued quarterly results by key index constituents and negative global cues.
However,  what the market missed is that IMF on 20 January also said global growth, estimated at 2.9% in 2019, is projected to increase to 3.3% in 2020 and inch up further to 3.4% in 2021 -- which means growth would continue though a tad below the estimates. This is positive for the BULLS. 
For India too,  the outlook looks much better in CY2020 than for FY20, as per the IMF commentary, which said: India's growth is estimated at 4.8% in 2019, projected to improve to 5.8% in 2020 and 6.5% in 2021 (1.2% and 0.9% lower than the October forecast), supported by monetary and fiscal stimulus as well as subdued oil prices. 
Therefore, I feel the investors should use every opportunity to buy good stocks in situations like today,  to reap superb benefits in the short to medium term.

#Buy the shares of Strides Parma Science Ltd at the CMP of Rs.390.40, for short term targets of Rs. 415/417. SL: Rs.382.
The company recently announced successful closure of the US drug regulator's inspection at its manufacturing site in Florida, United States.

Comments

Popular posts from this blog